CLINICAL SND FUNCTIONAL FEATURES OF ASTHMA IN REPUBLIC OF KARELIA

  • Authors: Lyulyu I.V.1, Mokhovikov G.I.1, Vezikova N.N.2, Kurevin A.I.3, Burygina E.V.4, Kozlova Y.I.4,5
  • Affiliations:
    1. State budgetary healthcare institution of the Republic of Karelia “Republican Hospital named after V.A. Baranova", Petrozavodsk, Russian Federation
    2. Medical Institute named after Professor A.P. Zilbera, Petrozavodsk
    3. State budgetary healthcare institution «City Clinic No.1», Petrozavodsk, Russian Federation
    4. Federal State Budgetary Educational Institution of Higher Education «North-Western State Medical University named after. I.I. Mechnikov», Saint Petersburg, Russian Federation
    5. State budgetary healthcare institution «City Multidisciplinary Hospital No.2» Saint Petersburg, Russian Federation
  • Section: Original study articles
  • Submitted: 07.03.2026
  • Accepted: 23.05.2026
  • Published: 02.06.2026
  • URL: https://rusalljournal.ru/raj/article/view/17119
  • DOI: https://doi.org/10.36691/RJA17119
  • ID: 17119


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Severe asthma is a socially significant problem. Despite ongoing therapy, many patients fail to achieve control over their symptoms. Significant interregional differences may exist in both the prevalence and the clinical course of severe asthma.

AIM: To assess the clinical and functional features of severe asthma in the Republic of Karelia in a real-world setting.

MATERIALS AND METHODS: The study included 94 adult patients with severe asthma (71.2% female), whose baseline therapy corresponded to steps IV–V according to the clinical guidelines (2024). The following parameters were assessed: spirometry results (bodyplethysmograph Ganshorn, PowerCube series, Switzerland), blood eosinophil count (Systex XN-1000 hematology analyzer, Japan), sputum eosinophil count (microscopy method), and total IgE levels (Mindray CL 1200i analyzer, China). The ACQ-5 (Asthma Control Questionnaire) and ACT (Asthma Control Test) questionnaires were used.

RESULTS: Uncontrolled course was established in 63 (67.0%) patients with severe asthma. The frequency of corticosteroid-dependent severe asthma was 14.8%. The majority of patients (94.6%) exhibited a T2 endotype of airway inflammation, with sensitization to ≥1 allergen in 58.5% of cases. In patients with severe asthma, the following comorbidities were registered: allergic rhinitis –48.9% patients, chronic rhinosinusitis with nasal polyps – 32.9%, and atopic dermatitis – 13.8%. Obesity was diagnosed in 49 (52.1%) patients. Biologic therapy for more than 12 months was administered to 15 (15.9%) patients.

CONCLUSION: Patients with severe asthma in the Republic of Karelia are characterized by an uncontrolled disease course, a predominance of the T2 endotype of airway inflammation, and the presence of T2-associated multimorbid pathology.

Full Text

Restricted Access

About the authors

Irina V. Lyulyu

State budgetary healthcare institution of the Republic of Karelia “Republican Hospital named after V.A. Baranova", Petrozavodsk, Russian Federation

Author for correspondence.
Email: luluirina@yandex.ru
ORCID iD: 0009-0002-8351-8413
SPIN-code: 4957-9480

врач аллерголог-иммунолог 

Russian Federation, 185000, Россия, Республика Карелия, Петрозаводск, ул. Пирогова,3

Gennady I. Mokhovikov

State budgetary healthcare institution of the Republic of Karelia “Republican Hospital named after V.A. Baranova", Petrozavodsk, Russian Federation

Email: mognadi@mail.ru
ORCID iD: 0000-0003-0041-293X
SPIN-code: 6310-1907

врач пульмонолог

185000, Россия, Республика Карелия, Петрозаводск, ул. Пирогова,3

Natalya N. Vezikova

Medical Institute named after Professor A.P. Zilbera, Petrozavodsk

Email: vezikov23@mail.ru
ORCID iD: 0000-0002-8901-3363
SPIN-code: 3910-7360
Russian Federation, 185910, Россия, Республика Карелия, Петрозаводск, проспект Ленина, 33

Artem I. Kurevin

State budgetary healthcare institution «City Clinic No.1», Petrozavodsk, Russian Federation

Email: akurevin@list.ru
Russian Federation, 185035,Россия, Республика Карелия, Петрозаводск, ул. Свердлова, 20

Ekaterina V. Burygina

Federal State Budgetary Educational Institution of Higher Education «North-Western State Medical University named after. I.I. Mechnikov», Saint Petersburg, Russian Federation

Email: katerina.burygina@mail.ru
ORCID iD: 0000-0002-9307-4927
SPIN-code: 3071-2552
Russian Federation, 191015, Россия, Санкт-Петербург, ул. Кирочная, 41

Yana I. Kozlova

Federal State Budgetary Educational Institution of Higher Education «North-Western State Medical University named after. I.I. Mechnikov», Saint Petersburg, Russian Federation; State budgetary healthcare institution «City Multidisciplinary Hospital No.2» Saint Petersburg, Russian Federation

Email: kozlova510@mail.ru
ORCID iD: 0000-0002-4602-2438
SPIN-code: 5842-6039
Scopus Author ID: 56893897500
ResearcherId: P-2899-2014
Russian Federation, 191015, Россия, Санкт-Петербург, ул. Кирочная, 41; 194354, Россия, Санкт-Петербург, Учебный переулок, 5

References

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Available from:http//ginasthma.org/reports/[Accessed 18 January 2025].
  2. Scelo G., Torres-Duque C.A., Maspero J., et al. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Annals of Allergy, Asthma & Immunology. 2024;132(1):42–53. doi: 10.1016/j.anai.2023.08.021.
  3. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V., et al. Prevalence, incidence, phenotypes and other characteristics of severe bronchial asthma in the Russian Federation. Pulmonology. 2018;28(3):341–358. doi: 10.18093/0869-0189-2018-28-3-341-358
  4. D'Amato M., Pastore D., Lupia C., Candia C., Bruni A., Garofalo E., et al. Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach. Journal of Clinical Medicine. 2025;14(13):4749. doi: 10.3390/jcm14134749
  5. Sergeeva G.R., Emelyanov A.V., Korovina O.V., et al. Severe bronchial asthma: characteristics of patients in clinical practice. Therapeutic Archive. 2015;87(12):26–31. doi: 10.17116/terarkh2015871226-31
  6. Svenningsen S., Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Frontiers in Medicine. 2017;4:158. doi: 10.3389/fmed.2017.00158.
  7. Sergeeva G.R., Emelyanov A.V., Leshenkova E.V., Znakhurenko A.A. Biomarkers of airway inflammation in patients with severe bronchial asthma in real clinical practice. Pulmonology. 2020;30(4):437–445. doi: 10.18093/0869-0189-2020-30-4-437-445.
  8. Chung K.F., Wenzel S.E., Brozek J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal. 2014;43(2):343–373. doi: 10.1183/09031936.00202013.
  9. Wang E., Wechsler M.E., Tran T.N., Heaney L.G., Jones R.C., Menzies-Gow A.N., et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157(4):790–804. doi: 10.1016/j.chest.2019.10.053.
  10. Kraposhina A.Yu., Demko I.V., Sobko E.A. Clinical, functional and immunological characteristics of severe bronchial asthma. Russian Journal of Allergy. 2023;20(2):152–162. doi: 10.36691/RJA6395.
  11. Data from the Republican Hospital named after V.A. Baranov (Republic of Karelia), 2025 (unpublished data).
  12. Olejnik A.E., Kuźnar-Kamińska B. Association of Obesity and Severe Asthma in Adults. Journal of Clinical Medicine. 2024;13(12):3474. doi: 10.3390/jcm13123474.
  13. Koebnick C., Fischer H., Daley M.F., Ferrara A., Horberg M.A., Waitzfelder B., et al. Interacting effects of obesity, race, ethnicity and sex on the incidence and control of adult-onset asthma. Allergy, Asthma & Clinical Immunology. 2016;12:50. doi: 10.1186/s13223-016-0155-8.
  14. van Bragt J.J.M.H., Adcock I.M., Bel E.H.D., Braunstahl G.J., Ten Brinke A., Busby J., et al.; SHARP Clinical Research Collaboration. Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal. 2020;55(1):1901163. doi: 10.1183/13993003.01163-2019.
  15. Aisanov Z.R., Kurbacheva O.M., Emelyanov A.V., Ignatova G.L., Teikhman L., Makarova Ya.Yu., et al. Disease burden and management features of patients with severe bronchial asthma in Russia: results of an international observational study. Therapeutic Archive. 2024;96(3):212–217. doi: 10.26442/00403660.2024.03.202627
  16. Lee T.Y., Price D., Yadav C.P., Roy R., Lim L.H.M., Wang E., et al. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma. Chest. 2024;166(1):28–38. doi: 10.1016/j.chest.2024.02.029.
  17. Denton E., Price D.B., Tran T.N., Canonica G.W., Menzies-Gow A., FitzGerald J.M., et al. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(7):2680–2688.e7. doi: 10.1016/j.jaip.2021.02.059.
  18. Sergeeva G.R., Emelyanov A.V. Efficacy and safety of immunobiological drugs in patients with severe bronchial asthma in real clinical practice. Therapeutic Archive. 2024;96(3):240–245. doi: 10.26442/00403660.2024.03.202626.
  19. Naumova V.V., Zykov K.A., Valenta R., Kovtun O.P., Beltyukov E.K., Smolenskaya O.G., et al. Targeted therapy for severe bronchial asthma: patient phenotyping and algorithm for selecting a genetically engineered biological drug. Medical Council. 2024;18(20):82–91. doi: 10.21518/ms2024-518.
  20. Busse W.W., Kraft M., Rabe K.F., Deniz Y., Rowe P.J., Ruddy M., Castro M. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. European Respiratory Journal. 2021;58(2):2003393. doi: 10.1183/13993003.03393-2020.
  21. Peters M.C., Mauger D., Ross K.R., Phillips B., Gaston B., Cardet J.C., et al. Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency. American Journal of Respiratory and Critical Care Medicine. 2020;202(7):973–982. doi: 10.1164/rccm.201909-1813OC
  22. Meulmeester F.L., Mailhot-Larouche S., Celis-Preciado C., Lemaire-Paquette S., Ramakrishnan S., Wechsler M.E., et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. The Lancet Respiratory Medicine. 2025;13(6):505–516. doi: 10.1016/S2213-2600(25)00037-2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press,

License URL: https://rusalljournal.ru/raj/about/submissions#copyrightNotice
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-42773 от  21.07.2009.